Among patients with systemic autoimmune rheumatic diseases, hospitalization due to COVID-19 was more than twice as likely in ...

Despite milder variants, patients with systemic autoimmune rheumatic diseases remain vulnerable to severe COVID-19 outcomes, ...

The cryptocurrency market is showing resilience as U.S. equities plunge and investors look to bitcoin as a potential hedge ...

The findings reinforce the potential of BRIUMVI in improving patient outcomes for those seeking an alternative to their previous anti-CD20 therapy. Furthermore, the article in CNS DRUGS offers an ...

CD20 × CD3 bispecific antibodies bind to both CD20 on malignant B cells and CD3 on T cells, bringing them into close proximity, which triggers T cell-mediated killing of the targeted B cells.

The results of Phase III trials of the CD20-targeted human monoclonal antibody (mAb) ofatumumab in rheumatoid arthritis and non-Hodgkin's lymphoma (NHL) dampen hopes on the potential of the drug ...

The results from the first human trial of ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of rheumatoid arthritis (RA) have recently been presented. Genovese et al.

The broader cryptocurrency market, represented by the CoinDesk 20 Index (CD20), lost around 3.3% of its value over the period. The sharp drop brings BTC’s performance down 1.7% for the week ...

Background: Pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma is a rare, indolent subtype of non-Hodgkin lymphoma ...

TG Therapeutics (TGTX) announced the publication of two journal articles one describing the evolution of CD20 treatments for multiple sclerosis ...